NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Epicutaneous immunotherapy for treating peanut allergy in children ID1255

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
 DBV Technologies (Viaskin Peanut, 	 All Wales Therapeutics and Toxicology
EPIT Peanut)	Centre
	 Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Allergy UK	Wales
Anaphylaxis Campaign	British National Formulary
South Asian Health Foundation	Care Quality Commission
Specialised Healthcare Alliance	Department of Health, Social Services
	and Public Safety for Northern Ireland
Professional groups	Healthcare Improvement Scotland
Association of Paediatric Emergency	Medicines and Healthcare products
Medicine	Regulatory Agency
British Society for Allergy and	National Association of Primary Care
Immunology	 National Pharmacy Association
Neonatal and Paediatric Pharmacists	NHS Alliance
Group	NHS Confederation
Royal College of General Practitioners	Scottish Medicines Consortium
Royal College of Nursing	Welsh Health Specialised Services
Royal College of Paediatrics & Child	Committee
Health	
Royal College of Pathologists	Possible comparator companies
Royal College of Physicians	None
Royal Society of Medicine	
UK Clinical Pharmacy Association	Relevant research groups
United Kingdom Primary	 Asthma, Allergy and Inflammation
Immunodeficiency Network	Research Charity
	David Hide Asthma and Allergy
<u>Others</u>	Research Centre
Department of Health and Social Care	Cochrane Airways Group
NHS England	Genomics England
NHS Leicester City CCG	MRC Clinical Trials Unit
NHS Newham CCG	National Institute for Health Research
Welsh Government	
	Associated Public Health groups
	Public Health England
	Public Health Wales

Provisional stakeholder list for the technology appraisal of epicutaneous immunotherapy for treating peanut allergy in children ID1255 Issue date: November 2020 © National Institute for Health and Care Excellence 2020. All rights reserved

Appendix C

Consultees	Commentators (no right to submit or appeal)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

-

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.